

**Biocon Biologics Limited**

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,  
Semicon Park Electronic City, Phase - II,  
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** [contact@bioconbiologics.com](mailto:contact@bioconbiologics.com)[www.bioconbiologics.com](http://www.bioconbiologics.com)

July 16, 2026

**Singapore Exchange Securities Trading Limited**

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

**Subject: Company Statement**

Please find enclosed the company statement titled ***"Biocon Malaysia Receives EMA Approval for New Drug Product Fill Finish Unit for Insulins"***.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

**For Biocon Biologics Limited**

---

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above



NOTIFICATION TO STOCK EXCHANGE

**COMPANY STATEMENT**

**Biocon Malaysia Receives EMA Approval for New Drug Product  
Fill Finish Unit for Insulins**

***Bengaluru, Karnataka, India, July 16, 2026***

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.

Supplies to Europe from this line are expected to begin from Q2FY27.

– Company Spokesperson